Table 1.

Salivary duct carcinoma patient characteristics.

	Metastatic/recurrent cohort	First-line androgen deprivation therapy	First-line chemotherapy	P-value
N	35	20	14
Age				0.21
Mean (SD)	64.9 (13.2)	67.25 (10.1)	63.8 (14.6)
Median	65	63	66
Q1, Q3	59, 75	59, 77	60.25, 73
Range	32–87	50–87	34–84
Gender				0.05
Female	2 (6%)	0	2 (14%)
Male	33 (94%)	20 (100%)	12 (86%)
Site				0.97
Parotid	32 (91%)	18 (90%)	13 (93%)
Submandibular	2 (6%)	1 (5%)	1 (7%)
Could not be specified	1 (3%)	1 (5%)	0
T stage				0.56
T1/T2	3 (9%)	3 (15%)	0
T3/T4	15 (71%)	13 (65%)	14 (100%)
TX	6 (17%)	4 (20%)	0
Could not be determined	1 (3%)	0	0
N stage				0.66
N0/N1	5 (15%)	5 (15%)	0
N2/N3	20 (58%)	10 (50%)	9 (64%)
NX	10 (29%)	5 (25%)	5 (36%)
M stage				0.15
M0	11 (31%)	8 (40%)	2 (14%)
M1	12 (34%)	7 (35%)	5 (36%)
MX	12 (34%)	5 (25%)	7 (50%)
Histology				0.34
Salivary duct carcinoma	28 (80%)	17 (85%)	10 (71%)
High-grade adenocarcinoma NOS	7 (20%)	3 (15%)	4 (28%)
Perineural invasion				0.03
Yes	20 (57%)	13 (65%)	7 (50%)
No	7 (20%)	3 (15%)	4 (29%)
Missing/Not applicable	8 (23%)	4 (20%)	3 (21%)
Extraparenchymal extension				0.24
Yes	23 (66%)	12 (60%)	10 (71%)
No	5 (14%)	4 (20%)	1 (7%)
Missing/Not applicable	7 (20%)	4 (20%)	3 (21%)
Androgen staining				0.23
Positive	34 (97%)	20 (100%)	13 (93%)
Negative	1 (3%)	0	1 (7%)
Lines of systemic treatment in metastatic setting				0.15
Mean (SD)	2.3 (1.8)	2.2 (1.6)	2.2 (1.8)
Median	2	2	2
Range	1–7	1–7	1–7